Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy

Objective: The aim of this study was to elicit willingness to pay (WTP) for allergen-specific subcutaneous injection immunotherapy (SCIT) in a cohort of respondents suffering from allergic-rhinoconjunctivitis (a-RC)/asthma, and to investigate how patients self-select to SCIT according to need. Methods: A random sample of the general population was screened for a-RC/asthma and asked if they were willing to consider SCIT. They were asked to state their WTP for SCIT by way of a discrete choice question (DC-q), an open-ended WTP question (o-WTP-q), and questions relating to their sociodemographic background and the severity of their a-RC/asthma. The characteristics of respondents demanding SCIT were compared with the characteristics of respondents who have actually received SCIT to establish possible barriers to demand. Results: Our results suggest that respondents do well in self-selecting themselves to SCIT on the basis of need according to disease burden measured in terms of a-RC classification, number of contacts with a general practitioner, number of sick days, and potential quality-adjusted life-year loss. Mean WTP for SCIT was estimated at €655 (median, €267) (o-WTP-q) and €903 (95 percent confidence limit, 348–1,459) (DC-q). Conclusion: Characteristics of respondents, who consider SCIT and are willing to pay for SCIT, suggest that allergy sufferers select themselves appropriately according to need and not according to other characteristics, such as income or education. There is a significant discrepancy between those who hypothetically consider SCIT and those demanding SCIT in real life. This study suggests that there are barriers to entry related to age and education, but not to income.

[1]  M. C. Lema Devesa [Economics, health, and health care]. , 2003, Neurologia.

[2]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[3]  Icek Ajzen,et al.  Explaining the Discrepancy between Intentions and Actions: The Case of Hypothetical Bias in Contingent Valuation , 2004, Personality & social psychology bulletin.

[4]  D. Jarvis,et al.  Change in prevalence of IgE sensitization and mean total IgE with age and cohort. , 2005, The Journal of allergy and clinical immunology.

[5]  E. Juniper,et al.  Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. , 1999, The Journal of allergy and clinical immunology.

[6]  B. Yawn,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update , 2008 .

[7]  A. Dirksen,et al.  Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. , 2000, The Journal of allergy and clinical immunology.

[8]  R. Dahl,et al.  Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. , 2008, Allergy.

[9]  Paul Kind,et al.  Variations in population health status: results from a United Kingdom national questionnaire survey , 1998, BMJ.

[10]  M A Koopmanschap,et al.  The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.

[11]  Thomas Laitila,et al.  Economic Valuation with Stated Preference Techniques: A Manual , 2004 .

[12]  R. Smith The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation. , 2001, Health economics.

[13]  A. Linneberg,et al.  Temporal trends of aeroallergen sensitization over twenty‐five years , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  B. O'brien,et al.  Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. , 1998, Journal of clinical epidemiology.

[15]  A. Linneberg,et al.  Remission of allergic rhinitis: An 8-year observational study. , 2004, The Journal of allergy and clinical immunology.

[16]  J. Bousquet,et al.  Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. , 1997, The Journal of allergy and clinical immunology.

[17]  S. Hurd,et al.  GINA guidelines on asthma and beyond * , 2007, Allergy.

[18]  R. Dahl,et al.  Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. , 2005, Allergologia et immunopathologia.

[19]  S. Durham,et al.  Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. , 2001, The Journal of allergy and clinical immunology.

[20]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[21]  W. Greene,et al.  计量经济分析 = Econometric analysis , 2009 .

[22]  George Loewenstein,et al.  Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public , 2003, Quality of Life Research.

[23]  Allergen injection immunotherapy for seasonal allergic rhinitis. , 2007, The Cochrane database of systematic reviews.

[24]  K. M. Pedersen,et al.  Værdisætning af sundhed: Teorien om kvalitetsjusterede leveår , 2003 .

[25]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[26]  N. York,et al.  Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study. , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.